drugset

drugset / Trial / NCT05703282

A Study to Assess the Safety and Pharmacokinetics of AD-104-A

NCT05703282 ↗

Phase 1 Completed 32 enrolled Addpharma Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-104-A

Timeline

Start: 2023-03-13
Primary completion: 2024-04-05
Completion: 2024-04-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AD-104-A	Unknown	—	Oral

Indications